Fig. 1From: A clinical perspective on the utility of alpha 1 antichymotrypsin for the early diagnosis of calcific aortic stenosisSchematic representation of the workflow. Samples were collected from valve replacement surgeries (AS) and autopsies (controls). During the discovery phase the whole tissue and secretome were analyzed and AACT was identified. Finally, AACT was validated as a potential biomarker in WBs, and by IHC and SRMBack to article page